Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:ALTSNASDAQ:ANABNASDAQ:AVXL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$2.44+3.0%$2.22$1.89▼$3.76$728.16M0.462.96 million shs3.80 million shsALTSJanone$10.21+4.9%$6.20$1.29▼$10.85$169.92M2.31228,508 shs333,550 shsANABAnaptysBio$23.70+12.1%$20.00$12.21▼$41.31$696.31M-0.2629,000 shs840,957 shsAVXLAnavex Life Sciences$8.27+6.3%$8.43$3.51▼$14.44$706.03M0.821.22 million shs1.19 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-2.07%+16.18%+17.04%+1.72%-36.80%ALTSJanone0.00%-1.62%+70.40%+89.67%+972,999,900.00%ANABAnaptysBio-0.61%-6.29%+5.07%+29.38%-15.17%AVXLAnavex Life Sciences+0.78%+1.97%-5.27%-10.27%+87.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.7242 of 5 stars3.42.00.00.02.73.30.6ALTSJanoneN/AN/AN/AN/AN/AN/AN/AN/AANABAnaptysBio1.9455 of 5 stars3.41.00.00.02.61.70.6AVXLAnavex Life Sciences3.9766 of 5 stars3.70.00.04.74.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.75Moderate Buy$8.33241.53% UpsideALTSJanone 0.00N/AN/AN/AANABAnaptysBio 2.80Moderate Buy$42.3878.80% UpsideAVXLAnavex Life Sciences 3.33Buy$44.00432.04% UpsideCurrent Analyst Ratings BreakdownLatest ALTS, ANAB, ABCL, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$22.00 ➝ $38.005/29/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.005/28/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $90.005/16/2025ABCLAbCellera BiologicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $10.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.004/16/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/31/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.003/26/2025ANABAnaptysBioJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$23.11M31.50N/AN/A$3.97 per share0.61ALTSJanone$18.05M9.88N/AN/A($0.67) per share-15.24ANABAnaptysBio$111.87M6.22N/AN/A$3.32 per share7.14AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.40M-$0.56N/AN/AN/A-533.32%-15.73%-12.22%8/5/2025 (Estimated)ALTSJanone-$7.81MN/A0.00∞N/AN/A-2,940.01%-39.81%N/AANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)AVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)Latest ALTS, ANAB, ABCL, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AALTSJanone$1.2211.95%N/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A9.349.34ALTSJanone1.960.750.75ANABAnaptysBioN/A10.2310.23AVXLAnavex Life SciencesN/A9.459.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%ALTSJanone6.27%ANABAnaptysBioN/AAVXLAnavex Life Sciences31.55%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%ALTSJanone4.90%ANABAnaptysBio33.50%AVXLAnavex Life Sciences11.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.66 millionOptionableALTSJanone17017.46 million13.38 millionN/AANABAnaptysBio10029.38 million20.17 millionOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableALTS, ANAB, ABCL, and AVXL HeadlinesRecent News About These CompaniesWellington Management Group LLP Acquires Shares of 158,674 Anavex Life Sciences Corp. (NASDAQ:AVXL)June 6 at 4:15 AM | marketbeat.comApella Capital LLC Acquires Shares of 98,555 Anavex Life Sciences Corp. (NASDAQ:AVXL)June 5 at 5:36 AM | marketbeat.comSquarepoint Ops LLC Boosts Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)June 3 at 3:57 AM | marketbeat.comBank of America Corp DE Sells 76,485 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)June 3 at 3:18 AM | marketbeat.comMillennium Management LLC Sells 133,208 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)June 2, 2025 | marketbeat.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by PVG Asset Management CorpMay 27, 2025 | marketbeat.comTwo Sigma Investments LP Decreases Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)May 27, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Purchases Shares of 105,130 Anavex Life Sciences Corp. (NASDAQ:AVXL)May 26, 2025 | marketbeat.comRafferty Asset Management LLC Sells 64,985 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)May 24, 2025 | marketbeat.comNoteworthy Tuesday Option Activity: TOL, AVXL, PIIMay 21, 2025 | nasdaq.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by Price T Rowe Associates Inc. MDMay 18, 2025 | marketbeat.comAnavex Life Sciences Corp.'s (NASDAQ:AVXL) largest shareholders are individual investors with 60% ownership, institutions own 37%May 17, 2025 | finance.yahoo.comDoes Anavex's Alzheimer's Drug Actually Confer Benefit?May 15, 2025 | seekingalpha.comThe Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)May 15, 2025 | seekingalpha.comAnavex Life Sciences (NASDAQ:AVXL) Announces Quarterly Earnings ResultsMay 15, 2025 | marketbeat.comAnavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comAnavex Life Sciences Corp. Reports Q2 Fiscal 2025 Financial Results and Updates on Clinical DevelopmentsMay 15, 2025 | nasdaq.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2025 Earnings Call TranscriptMay 15, 2025 | insidermonkey.comAnavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ...May 15, 2025 | finance.yahoo.comAnavex Life Sciences to Participate at Upcoming Healthcare ConferencesMay 14, 2025 | globenewswire.comAnavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALTS, ANAB, ABCL, and AVXL Company DescriptionsAbCellera Biologics NASDAQ:ABCL$2.44 +0.07 (+2.95%) Closing price 04:00 PM EasternExtended Trading$2.47 +0.03 (+1.39%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Janone NASDAQ:ALTS$10.21 +0.48 (+4.93%) Closing price 04:00 PM EasternExtended Trading$10.12 -0.09 (-0.83%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.AnaptysBio NASDAQ:ANAB$23.70 +2.56 (+12.11%) Closing price 04:00 PM EasternExtended Trading$23.71 +0.01 (+0.04%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Anavex Life Sciences NASDAQ:AVXL$8.27 +0.49 (+6.30%) Closing price 04:00 PM EasternExtended Trading$8.28 +0.02 (+0.18%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
